Available in other languages:
The increasing frequency of avian influenza outbreaks worldwide is accelerating the growth of the global avian influenza vaccine market, according to a report by Exactitude Consultancy.
Expanding poultry meat and egg production, government-led vaccination campaigns, and advances in recombinant and vector vaccine technology are reinforcing this trend. Greater emphasis on animal health surveillance and traceability is also supporting market growth.
Exactitude Consultancy projects the market, valued at USD 1.34 billion in 2024, will reach USD 2.19 billion by 2034. This represents a compound annual growth rate of 5.0 percent during 2025–2034. Rising concerns over zoonotic transmission, trade losses, and food security have positioned vaccination as a critical component of animal health management across Asia, Europe, and the Americas.
Avian influenza, commonly known as bird flu, continues to threaten poultry populations worldwide, affecting both commercial farms and backyard systems.
To mitigate economic and public health risks, governments and producers are adopting preventive vaccination strategies alongside enhanced biosecurity measures.
Traditional inactivated virus vaccines remain the backbone of disease control programs, accounting for more than 60% of market share. However, next-generation recombinant and vector-based vaccines are gaining traction. These advanced formulations provide broad, cross-protective immunity and enable differentiation of infected from vaccinated animals (DIVA) strategies.
The growing frequency of highly pathogenic avian influenza (HPAI) outbreaks and the rise in industrial-scale poultry farming are further accelerating vaccine demand.
“Avian influenza vaccination is no longer optional; it’s an essential pillar of global food security. With advances in recombinant and vector-based vaccines, producers can now achieve broader immunity and sustainable disease control,” said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.
Between 2025 and 2034, Exactitude Consultancy expects the market to evolve toward universal and recombinant formulations capable of addressing multiple viral strains.
Between 2025 and 2034, Exactitude Consultancy expects the market to evolve toward universal and recombinant formulations capable of addressing multiple viral strains.
Regionally, Asia Pacific is projected to remain the largest market due to high poultry density and frequent virus recurrence. Europe and North America are expected to adopt innovative DIVA-compatible vaccines that balance disease control with trade policies.
Their report concluded that:
Subscribe now to the poultry technical magazine
AUTHORS
Newcastle Disease: One Hundred Years On, Why Transmission Control Matters More Than Ever
Mustafa Seckin Sandikli
Egg Size Versatility in Nick Chick – Part I
H&N Technical Department
Interview with Khaled Abdel Nasser Awwad
Khaled Abdel Nasser Awwad
When the Supply Chain Breaks: Poultry Prices and the Economics of Maritime Disruption in the Middle East
Dima Chatila
Reovirus Infections in the Broiler Industry
Edgar O. Oviedo Rondón
Egg Condensation in Hatcheries: A Hidden Risk for Embryo Development, Hatchability and Chick Quality
Rasel Ahmed
From Chat to Farm Insight: Bridging the Social Data Gap in Indonesian Broiler Farming
Setiawan Guntarto
Labor Shortage in the Poultry Industry: Potential Solutions
Edgar O. Oviedo Rondón
A Comparison of Soybean Meal from Different Origins in Terms of Nutrient Composition, Amino Acid Profile, and Protein Quality
Güner GÖVENÇ
When Algorithms Start to Control Feed Composition
Henri E. Prasetyo DVM. M.Vsc
